CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]
Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yahoo! Finance]